Immune-Onc Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
795 San Antonio Rd, Palo Alto, Californi...Phone Number
(650) 457-1741Website
www.immune-onc.comRevenue
$7 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Immune-Onc Therapeutics
Founded in 2016, Immune-Onc Therapeutics is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients, headquartered in Palo Alto, CA.Explore more
Immune-Onc Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immune-Onc Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Immune-Onc Therapeutics has new funding data
Product Launch: Get notified when Immune-Onc Therapeutics launches new products
Click to see if Immune-Onc Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Immune-Onc Therapeutics
Website visits: Recent activity has been detected on your website
Check out if Immune-Onc Therapeutics is spiking on competitors!
Earning: See what the market has to say on Immune-Onc Therapeutics recently announced quarterly report
Immune-Onc Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Immune-Onc Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Immune-Onc Therapeutics
Find more new buyers
Compare Similar Companies to Immune-Onc Therapeutics
Compare insights from companies similar to Immune-Onc Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immune-Onc Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immune-Onc Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immune-Onc Therapeutics.
Immune-Onc Therapeutics financials insights
Gather financial insights about Immune-Onc Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$7M
2020
Debt
$150K
2023
Series B
$131M
Immune-Onc Therapeutics Tech Stack
A closer look at the technologies used by Immune-Onc Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Funding
Executive Move
Board of Directors
Executive Move
Board of Directors
Immune-Onc Therapeutics News & Media
Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting
PALO ALTO, Calif.--(BUSINESS WIRE)-- #ASH2024--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today presented updated data from its Phase 1b expansion cohort evaluating IO-202, a first-in-class anti-LILRB4 antibody, in combination with azacitidine (AZA) in patients with chronic myelomonocytic leukemia (CMML). These new findings were highlighted inImmune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
PALO ALTO, Calif.--(BUSINESS WIRE)-- #AML--Immune-Onc Therapeutics to Present Additional Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with CMML at 2024 EHA Annual Congress.Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
PALO ALTO, Calif.--(BUSINESS WIRE)-- #CMML--Immune-Onc Announces IO-202 CMML Interim Data at EHA2024Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by US FDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic Myelomonocytic Leukemia (CMML)
PALO ALTO, Calif.--(BUSINESS WIRE)-- #AML--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML). IO-202 received Fast Track Designation for treatment of relapsed or refractory CMML in 2023. I
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Immune-Onc Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2016, Immune-Onc Therapeutics is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients, headquartered in Palo Alto, CA.... Read More
